Skip to main content
OpenTrials
Completed

NCT Number: NCT04879927

Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement

The purpose of this research is to understand how screening for patient resource needs followed by customized resource matching can improve outcomes for adults with breast, lung or gastrointestinal cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Cancer Gastrointestinal Diseases Gastrointestinal Neoplasms Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Skin Diseases Skin and Connective Tissue Diseases Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States

About this study

This research study is an intervention assessment; this is the first-time investigators are examining the impact of screening for resource needs followed by customized resource matching at Dana-Farber Cancer Institute.

  • The research study procedures include screening for social determinants of health (resource) needs and, depending on study group, resource matching.
  • Participants will be randomized into one of two groups.
  • Usual Care or Usual Care with customized resource matching.

It is expected that about 125 participants will take part in this research study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Eligible patients will be adults age 18 or older, able to consent, scheduled for a new patient consultation in DFCI BOC, TOP or GCC. To select for patients from demographic groups vulnerable to SDoH needs, two different groups will be eligible to participate.
  • Group A
  • BIPOC (Black, Latinx, Native American or Pacific Islander)
  • LEP Spanish-speaking (As indicated by the EHR)
  • Low SES (from zip code with median household income <$32,000/year) OR
  • Age 70+
  • Group B
  • Any one NPIQ response indicating SDoH need
  • Health literacy/numeracy, Caregiving/relationships, OR Finances

Exclusion criteria

  • Group A and B

-- Patients not continuing care at Dana Farber Cancer Institute

Treatment and study plan

Resource Matching

Other

Resource staff involved in the customized resource matching arm of the intervention will include staff from DFCI Patient Services and DFCI Financial Counseling. Financial counseling will support patients with financial resource needs. DFCI Patient Services will provide assistance for all other patient Social Determinants of Health needs.

Usual Care

Other

Patients randomized to the control group will receive a pre-existing pamphlet detailing DFCI resources.

Primary outcomes

  1. Number of Patients Treatment Interruption

    Time frame: 30 Days

    Number of interruptions to cancer treatment (defined here as treatment hold, reduction, discontinuation or ED visits/hospitalizations as indicated by the patient medical record)

  2. Number of Patients Treatment Interruption

    Time frame: 90 Days

    Number of interruptions to cancer treatment (defined here as treatment hold, reduction, discontinuation or ED visits/hospitalizations as indicated by the patient medical record)

  3. Number of Patients Treatment Interruption

    Time frame: 180 Days

    Number of interruptions to cancer treatment (defined here as treatment hold, reduction, discontinuation or ED visits/hospitalizations as indicated by the patient medical record)

  4. Rate of Treatment Interruption

    Time frame: 00 Days

    Rate of interruptions to cancer treatment (defined here as treatment hold, reduction, discontinuation or ED visits/hospitalizations as indicated by the patient medical record)

  5. Rate of Treatment Interruption

    Time frame: 90 Days

    Rate of interruptions to cancer treatment (defined here as treatment hold, reduction, discontinuation or ED visits/hospitalizations as indicated by the patient medical record)

  6. Rate of Treatment Interruption

    Time frame: 180 Days

    Rate of interruptions to cancer treatment (defined here as treatment hold, reduction, discontinuation or ED visits/hospitalizations as indicated by the patient medical record)

Sponsors and collaborators

Lead sponsor

Dana-Farber Cancer Institute

Other

Registry information

Acronym: RESOURCE

Important dates

Study start
2021
Primary completion
2022
Study completion
2023
First posted
May 10, 2021
Registry last updated
May 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.